Results derived from the KRYSTAL-1 first-in-human Phase I/II clinical trial (NCT03785249) showed its safety and efficacy as monotherapy in previously treated KRAS-G12C NSCLC patients.371,379 At the recommended dose, the observed ORR stood at 42.9%, PFS was 6.5 months, and the median OS extended to 12.6 months.371 These positive findings substantiated the FDA’s accelerated approval of adagrasib in December 2022 for treating patients with locally advanced or metastatic NSCLC harboring KRAS-G12C mutations who have previously received at least one systemic therapy. This evidence concerns the gene KRAS and non-small cell lung carcinoma.